Understand the source comparison
Comparison to Other Myostatin Inhibitors
How does ACE-031 safety compare to related approaches? vs. Myostatin antibodies: Similar vascular safety concerns (epistaxis); ACE-031’s Fc region may provide slight advantage in tolerability vs. Follistatin: Both inhibit activin; similar epistaxis risk; diffe
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- How does ACE-031 safety compare to related approaches?
- vs. Myostatin antibodies: Similar vascular safety concerns (epistaxis); ACE-031’s Fc region may provide slight advantage in tolerability
- vs. Follistatin: Both inhibit activin; similar epistaxis risk; different immunogenic profiles
- vs. Myostatin gene therapy: ACE-031 is reversible; gene therapy is not. This may provide safety advantage
- vs. Growth factors (MGF, IGF-1): ACE-031 avoids growth factor risks (off-target growth stimulation) but carries vascular risks; different safety profiles
- Overall, ACE-031’s safety profile is comparable to or better than alternative myostatin inhibition strategies.